Stay updated on BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial

Sign up to get notified when there's something new on the BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy or safety evaluation of CIN-107 compared to placebo after 12 weeks of treatment in patients with treatment-resistant hypertension (rHTN). This change may reflect new data or findings in the Phase 2 study of CIN-107.
    Difference
    0.1%
    Check dated 2024-06-06T14:42:57.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying requirements such as being on a stable regimen of antihypertensive agents and compliance with medication, among other health-related conditions.
    Difference
    19%
    Check dated 2024-05-22T20:58:43.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:21:56.000Z thumbnail image

Stay in the know with updates to BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial

Enter your email address, and we'll notify you when there's something new on the BrigHTN Study of CIN-107 in Treatment-Resistant Hypertension Clinical Trial page.